Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation Development Post published:August 22, 2023 Post category:Press Release
Revive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare Agents Post published:July 28, 2023 Post category:Press Release
Revive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Post published:July 6, 2023 Post category:Press Release
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19 Post published:May 2, 2023 Post category:Press Release
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech Post published:April 3, 2023 Post category:Press Release
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder Post published:March 28, 2023 Post category:Press Release
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Post published:March 20, 2023 Post category:Press Release
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19 Post published:March 8, 2023 Post category:Press Release
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development Post published:February 6, 2023 Post category:Press Release
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Post published:February 3, 2023 Post category:Press Release